Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (66)

II-01Nina Scherer

A population pharmacokinetic (PK) model of metformin regarding immediate and extended release formulations under fasted and fed conditions

Wednesday 15:10-16:30

II-02Emilie Schindler

The minimal continuous-time Markov pharmacometric model

Wednesday 15:10-16:30

II-03Rik Schoemaker

nlmixr: an open-source package for pharmacometric modelling in R

Wednesday 15:10-16:30

II-04Johannes Schropp

Target-mediated drug disposition model for a bispecific antibody: development of full model and quasi-equilibrium like approximation

Wednesday 15:10-16:30

II-05Pascal Schulthess

Frequency-domain response analysis for quantitative systems pharmacology models

Wednesday 15:10-16:30

II-06Bernard Sebastien

Pharmacokinetic/Pharmacodynamic Modelling of Recurrent Adverse Events as Function of Drug Concentration and Time

Wednesday 15:10-16:30

II-07Malte Selch Larsen

Using repeated-time-to-event modelling and simulation of spontaneous bleeding events in the F8 KO rat model for informed decision making of study design

Wednesday 15:10-16:30

II-08Marina Senek

Population pharmacokinetic model for levodopa/carbidopa microtablets in Parkinson’s disease patients and healthy subjects

Wednesday 15:10-16:30

II-09Jennifer Sheng

Joint modeling of time-varying exposure data and progression-free survival in elotuzumab-treated patients with relapsed/refractory multiple myeloma

Wednesday 15:10-16:30

II-10Satoshi Shoji

Slow drug-target complex kinetics and first dose overestimation of free target suppression in target-mediated drug disposition (TMDD) approximation models: An evaluation for tanezumab a NGF antibody for treatment of pain

Wednesday 15:10-16:30

II-11Mahendra Shukla

Population Pharmacokinetic-Pharmacodynamic modeling of furosemide for anti-hypertensive effect

Wednesday 15:10-16:30

II-13Sarah Siederer

Model Based Extrapolation Approach Driving a Streamlined Clinical Development Plan for Inhaled Oxytocin

Wednesday 15:10-16:30

II-14Giovanni Smania

The role of modelling and simulation in the paediatric investigation plan of a xanthine oxidase inhibitor for tumor lysis syndrome prevention

Wednesday 15:10-16:30

II-15Konstantina Soulele

Population pharmacokinetic analysis of inhaled budesonide in asthma patients

Wednesday 15:10-16:30

II-17Sabine Stuebler

Towards a systems biology model for inflammatory bowel disease

Wednesday 15:10-16:30

II-19Waroonrat Sukarnjanaset

Performance of FOCEI vs SAEM in simple population pharmacokinetic analysis of rich, medium and sparse data.

Wednesday 15:10-16:30

II-20Monika Sundqvist

Preclinical pharmacokinetic-pharmacodynamic modelling to guide first-time-in-human studies with the anti-miR-103/107, RG-125 (AZD4076)

Wednesday 15:10-16:30

II-21Ajit Suri

Population Pharmacokinetic Modeling of Brentuximab Vedotin, a CD30-Directed Antibody-Drug Conjugate, and its cytotoxic payload (MMAE) in Patients With Various Hematological Malignancies

Wednesday 15:10-16:30

II-22Elin Svensson

Linking rifampicin exposure to treatment response over 6 months in patients with pulmonary tuberculosis

Wednesday 15:10-16:30

II-23Lénaïg Tanneau

Bedaquiline’s exposure-response relationship evaluated with data from the observational study C209

Wednesday 15:10-16:30

II-24Joel Tarning

Population pharmacokinetic properties of piperaquine in falciparum malaria: An individual participant data meta-analysis

Wednesday 15:10-16:30

II-25Adrien Tessier

Investigating the PK/PD relationship of a new pro-apoptotic drug through tumor growth inhibition modelling in NUDE rats

Wednesday 15:10-16:30

II-26Donato Teutonico

Development of a PBPK model to describe late colonic absorption after oral administration

Wednesday 15:10-16:30

II-27Tjokosela Tikiso

Population Pharmacokinetics of Abacavir in HIV-infected African children

Wednesday 15:10-16:30

II-28Valentina Topic Vucenovic

Nonlinear mixed effects modelling approach for investigation of 131I kinetics in patients with benign thyroid disease

Wednesday 15:10-16:30

II-29Elena Tosca

A PK/PD model for tumor-in-host growth kinetics following administration of an antiangiogenic agent given alone or in combination regimens

Wednesday 15:10-16:30

II-30Mirjam Trame

Translational in-vitro in-vivo model to correlate HIPS derived cardiomyocyte contractility assay and in-vivo dog telemetry based dPdtmax measurements

Wednesday 15:10-16:30

II-31Alexios Tsiligiannis

Optimization of a paediatric FDC tablet and dosing regimen for the first line treatment of tuberculosis.

Wednesday 15:10-16:30

II-32Periklis Tsiros

Bayesian Whole Body Population Physiologically Based Pharmacokinetic Approach for Characterization of Interindividual Variability of Diazepam

Wednesday 15:10-16:30

II-33Eirini Tsotsou

Population pharmacokinetics of gentamycin in hospitalized ICU patients

Wednesday 15:10-16:30

II-34Denise Feick

Physiologically-Based Pharmacokinetic (PBPK) Modeling of the CYP2C8 Substrate Pioglitazone

Wednesday 15:10-16:30

II-35Zofia Tylutki

Simulation of pharmacokinetics of amitriptyline and nortriptyline and their common effect on human cardiac electrophysiology in healthy population

Wednesday 15:10-16:30

II-36Sebastian Ueckert

Solving linear ODEs using Krylov subspace projection methods

Wednesday 15:10-16:30

II-37Sami Ullah

Population pharmacokinetic analysis of intravenous telavancin in healthy subjects undergoing plasma and tissue microdialysis

Wednesday 15:10-16:30

II-38Moreno Ursino

dfpk: an R package for a practical implementation of PK measurements in dose-finding studies

Wednesday 15:10-16:30

II-39Pavan Vaddady

A Comprehensive Model-Based Meta-Analysis (MBMA) of Diabetes Studies in Type 2 Diabetes Mellitus Patients to Quantify the Relationship between HbA1c and Fasting Plasma Glucose

Wednesday 15:10-16:30

II-40Elodie Valade

Population Pharmacokinetic Modeling of Simeprevir – Odalasvir Interaction in Healthy Volunteers

Wednesday 15:10-16:30

II-41Tamara van Donge

Impact of rise in anti-drug antibodies on the pharmacokinetics of the monoclonal antibody adalimumab

Wednesday 15:10-16:30

II-42Michiel Van Esdonk

Quantifying the growth hormone lowering effect of BIM23B065 after a GH stimulation test

Wednesday 15:10-16:30

II-43Eline van Maanen

A systems pharmacology approach unravels the dynamics of the APP pathway and unfolds Aß oligomer modulation

Wednesday 15:10-16:30

II-44Erno van Schaick

CHF5993 a triple combination therapy for COPD patients: population PK modelling of formoterol following pMDI inhalation

Wednesday 15:10-16:30

II-45Rob van Wijk

A parent-metabolite pharmacokinetic model of paracetamol in zebrafish

Wednesday 15:10-16:30

II-46Marc Vandemeulebroecke

Multi-state modeling and simulation of patient trajectories after allogeneic hematopoietic stem cell transplantation (allo-HSCT) to inform drug development

Wednesday 15:10-16:30

II-47Swantje Völler

Normalisation weight in a covariate function affects the relative standard error of clearance: an example with paediatric data

Wednesday 15:10-16:30

II-48Veronika Voronova

Evaluation of immediate release exenatide effects on gastric motility and intestinal glucose absorption using a systems pharmacology model

Wednesday 15:10-16:30

II-49Janet Wade

Population PK analysis of Sym004 and the influence of variations in base model structure on covariate model building

Wednesday 15:10-16:30

II-50Thanaporn Wattanakul

Population pharmacokinetics and cardiovascular safety of piperaquine in African patients with uncomplicated malaria

Wednesday 15:10-16:30

II-51Sebastian Weber

Bayesian Pharmacokinetic Extrapolation from Dense Adult to Sparse Pediatric Data

Wednesday 15:10-16:30

II-52Janak Wedagedera

Statistical Power Analysis to Detect Drug-Drug Interaction between Lorezapam and Probenecid in Healthy and Renal-impaired Populations Using PBPK Modelling and the Simcyp R Package

Wednesday 15:10-16:30

II-53Gustaf Wellhagen

Impact of genotype assumption in a semi-mechanistic PK model of metformin

Wednesday 15:10-16:30

II-54Thomas Wendl

The Open Systems Pharmacology Suite (PK-Sim® & MoBi®): An open source solution for whole-body physiologically based pharmacokinetics and -dynamics

Wednesday 15:10-16:30

II-55Sebastian Wicha

The purpose determines the predictive performance: Comparison of four population pharmacokinetic models of methotrexate.

Wednesday 15:10-16:30

II-56Mélanie Wilbaux

Effects of Formula Milk on Weight Changes in Healthy Term and Preterm Neonates

Wednesday 15:10-16:30

II-57Francis Williams Ojara

Examining the relationship between paclitaxel exposure and peripheral neuropathy in non-small cell lung cancer

Wednesday 15:10-16:30

II-58Jan-Georg Wojtyniak

Physiologically-based Pharmacokinetic (PBPK) Modeling of Simvastatin Drug-Drug Interactions with Rifampin, Clarithromycin and Drug-Gene Interaction with ABCG2

Wednesday 15:10-16:30

II-60Gudrun Wuerthwein

Population Pharmacokinetics to model the time-varying clearance of the PEGylated asparaginase Oncaspar® in children with ALL

Wednesday 15:10-16:30

II-61Rujia Xie

Population pharmacokinetics of PF-04447943 in healthy volunteers (HV), adult patients with Alzheimer’s disease (AD) and patients with Sickle Cell Disease (SCD)

Wednesday 15:10-16:30

II-62Joao Paulo Ximenez

Population pharmacokinetic of tamoxifen and its metabolites in breast cancer patients

Wednesday 15:10-16:30

II-63Christine Xu

Population pharmacokinetics of sarilumab in patients with rheumatoid arthritis

Wednesday 15:10-16:30

II-64Dong-Seok Yim

Discrepancy between in vitro potency and in vivo efficacy in human – Implications in PK-PD modeling

Wednesday 15:10-16:30

II-65Anyue Yin

Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis

Wednesday 15:10-16:30

II-66Gunnar Yngman

Practical considerations for using the full random effects modeling (FREM) approach to covariate modeling

Wednesday 15:10-16:30

II-67Zakaria Zaril

A Mechanistic Pharmacokinetic Approach to the Development of Predictive Models in HIV-malaria co-infection.

Wednesday 15:10-16:30

II-68Chiara Zecchin

Quantitative modelling to assess target engagement and pharmacology in early clinical development of an anti-OSM humanised mAb

Wednesday 15:10-16:30

II-69Meng Zhaoling

Exposure/Response modeling for sarilumab dose regimens benefit/risk assessment

Wednesday 15:10-16:30

II-70Jochen Zisowsky

Simulation Study on a Method for PK-QT Analyses When Several Active Compounds or Metabolites Are Present

Wednesday 15:10-16:30